1057 related articles for article (PubMed ID: 15935238)
21. Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder.
MacMillan CM; Withney JE; Korndörfer SR; Tilley CA; Mrakotsky C; Gonzalez-Heydrich JM
J Psychiatr Pract; 2008 May; 14(3):160-9. PubMed ID: 18520785
[TBL] [Abstract][Full Text] [Related]
22. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Nasrallah HA; Brecher M; Paulsson B
Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
[TBL] [Abstract][Full Text] [Related]
23. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms.
McIntyre RS; Konarski JZ; Jones M; Paulsson B
J Affect Disord; 2007; 100 Suppl 1():S5-14. PubMed ID: 17391773
[TBL] [Abstract][Full Text] [Related]
24. Divalproex in the treatment of bipolar depression: a placebo-controlled study.
Davis LL; Bartolucci A; Petty F
J Affect Disord; 2005 Apr; 85(3):259-66. PubMed ID: 15780695
[TBL] [Abstract][Full Text] [Related]
25. Effects of divalproex versus lithium on length of hospital stay among patients with bipolar disorder.
Dalkilic A; Diaz E; Baker CB; Pearsall HR; Woods SW
Psychiatr Serv; 2000 Sep; 51(9):1184-6. PubMed ID: 10970927
[TBL] [Abstract][Full Text] [Related]
26. Drug interactions of lithium and other antimanic/mood-stabilizing medications.
Dunner DL
J Clin Psychiatry; 2003; 64 Suppl 5():38-43. PubMed ID: 12720483
[TBL] [Abstract][Full Text] [Related]
27. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder.
Bowden CL
J Clin Psychiatry; 2005; 66 Suppl 3():12-9. PubMed ID: 15762830
[TBL] [Abstract][Full Text] [Related]
28. Treatments for late-life bipolar disorder.
Aziz R; Lorberg B; Tampi RR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):347-64. PubMed ID: 17296540
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.
Woodward TC; Tafesse E; Quon P; Lazarus A
Pharmacoeconomics; 2010; 28(9):751-64. PubMed ID: 20623994
[TBL] [Abstract][Full Text] [Related]
30. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder.
Ketter TA
J Clin Psychiatry; 2008; 69 Suppl 5():9-15. PubMed ID: 19265635
[TBL] [Abstract][Full Text] [Related]
31. Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care.
Stensland MD; Jacobson JG; Nyhuis A
J Affect Disord; 2007 Aug; 101(1-3):187-93. PubMed ID: 17254637
[TBL] [Abstract][Full Text] [Related]
32. Decision tree for the treatment of bipolar disorder.
Sachs GS
J Clin Psychiatry; 2003; 64 Suppl 8():35-40. PubMed ID: 12892540
[TBL] [Abstract][Full Text] [Related]
33. Estimation of resource utilisation difference between lithium and valproate treatment groups from the VALID study.
Li SC; Aggarwal SK
J Med Econ; 2011; 14(3):350-6. PubMed ID: 21542675
[TBL] [Abstract][Full Text] [Related]
34. The effectiveness of divalproate in all forms of mania and the broader bipolar spectrum: many questions, few answers.
Bowden C
J Affect Disord; 2004 Apr; 79 Suppl 1():S9-14. PubMed ID: 15121342
[TBL] [Abstract][Full Text] [Related]
35. Long-term effectiveness and cost of a systematic care program for bipolar disorder.
Simon GE; Ludman EJ; Bauer MS; Unützer J; Operskalski B
Arch Gen Psychiatry; 2006 May; 63(5):500-8. PubMed ID: 16651507
[TBL] [Abstract][Full Text] [Related]
36. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes.
Revicki DA; Paramore LC; Sommerville KW; Swann AC; Zajecka JM;
J Clin Psychiatry; 2003 Mar; 64(3):288-94. PubMed ID: 12716270
[TBL] [Abstract][Full Text] [Related]
37. Functional outcomes in first-episode patients with bipolar disorder: a prospective study from the Systematic Treatment Optimization Program for Early Mania project.
Kauer-Sant'Anna M; Bond DJ; Lam RW; Yatham LN
Compr Psychiatry; 2009; 50(1):1-8. PubMed ID: 19059506
[TBL] [Abstract][Full Text] [Related]
38. Divalproex in the treatment of bipolar disorder.
Keck PE; McElroy SL
Psychopharmacol Bull; 2003; 37 Suppl 2():67-73. PubMed ID: 15021862
[TBL] [Abstract][Full Text] [Related]
39. Predictors of response to divalproex and lithium.
Bowden CL
J Clin Psychiatry; 1995; 56 Suppl 3():25-30. PubMed ID: 7883739
[TBL] [Abstract][Full Text] [Related]
40. Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo.
Bowden CL; Collins MA; McElroy SL; Calabrese JR; Swann AC; Weisler RH; Wozniak PJ
Neuropsychopharmacology; 2005 Oct; 30(10):1932-9. PubMed ID: 15956987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
